Bexarotene: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Bexarotene. Educational only — not medical advice.
Labeled uses
Targretin (bexarotene) gel 1% is indicated for the topical treatment of cutaneous lesions in patients with CTCL (Stage IA and IB) who have refractory or persistent disease after other therapies or who have not tolerated other therapies.
Source: FDA labeling via NIH DailyMed (set d35b4697…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.